image credit: Adobe Stock

Investors take root in Aspen Neuroscience’s customized cell therapy as $147.5M round closes

May 9, 2022

Aspen Neuroscience, a biotech developing the first autologous neuron replacement for Parkinson’s disease, is seeing double, as investors have flooded the company’s series B with $147.5 million following an initial $70 million round two years ago.

The private neurodegenerative disease biotech’s second funding round was co-led by venture capital firm and Alphabet spin-out GV, LYFE Capital and Revelation Partners. Additional new investors include Newton Investment Management, EDBI, LifeForce Capital, Medical Excellence Capital Partners, Mirae Asset Capital, NS Investment, among others.

Read More on FierceBiotech